Mohammed Abdelsaid1, Handong Ma1, Maha Coucha2, Adviye Ergul3. 1. Charlie Norwood Veterans Administration Medical Center, University of Georgia College of Pharmacy, USA; Department of Physiology, Georgia Regents University, Augusta, GA, USA. 2. Department of Physiology, Georgia Regents University, Augusta, GA, USA. 3. Charlie Norwood Veterans Administration Medical Center, University of Georgia College of Pharmacy, USA; Center for Pharmacy and Experimental Therapeutics, University of Georgia College of Pharmacy, USA; Department of Physiology, Georgia Regents University, Augusta, GA, USA. Electronic address: aergul@gru.edu.
Abstract
AIMS: Up-regulation of the endothelin (ET) system in type-2 diabetes increases contraction and decreases relaxation in basilar artery. We showed that 1) ET-receptor antagonism prevents diabetes-mediated cerebrovascular dysfunction; and 2) glycemic control prevents activation of the ET-system in diabetes. Here, our goal is to determine whether and to what extent glycemic control or ET-receptor antagonism reverses established cerebrovascular dysfunction in diabetes. MAIN METHODS: Non-obese type-2 diabetic Goto-Kakizaki rats were administered either vehicle, metformin (300 mg/kg/day) or dual ET-receptor antagonist bosentan (100mg/kg) for 4-weeks starting at 18-weeks after established cerebrovascular dysfunction (n=5-6/group). Control group included vehicle-treated aged-matched Wistar rats. Blood glucose and pressure were monitored weekly. At termination, basilar arteries were collected and cumulative dose-response curves to ET-1 (0.1-500 nM), 5-HT (1-1000 nM) and acetylcholine (Ach, 0.1 nM-5 μM) were studied by wire myograph. Middle cerebral artery (MCA) myogenic reactivity and tone were measured using pressurized arteriograph. KEY FINDINGS: There was no difference in ET-1 and 5-HT-mediated constrictions. Endothelium-dependent relaxation was impaired in diabetes. Bosentan improved sensitivity to Ach as well as the maximum relaxation. Myogenic-tone is decreased over the course of the disease. Both treatments improved the ability of MCAs to develop tone at 80 mm Hg and only bosentan improved the tone at higher pressures. SIGNIFICANCE: These results suggest that contractile response is not affected by glycemic control or ET-receptor antagonism. Meanwhile, dual ET-receptor blockade is effective in partially improving endothelium-dependent relaxation and myogenic response in a blood pressure-independent manner even after established cerebrovascular dysfunction and offers therapeutic potential. Published by Elsevier Inc.
AIMS: Up-regulation of the endothelin (ET) system in type-2 diabetes increases contraction and decreases relaxation in basilar artery. We showed that 1) ET-receptor antagonism prevents diabetes-mediated cerebrovascular dysfunction; and 2) glycemic control prevents activation of the ET-system in diabetes. Here, our goal is to determine whether and to what extent glycemic control or ET-receptor antagonism reverses established cerebrovascular dysfunction in diabetes. MAIN METHODS:Non-obese type-2 diabetic Goto-Kakizaki rats were administered either vehicle, metformin (300 mg/kg/day) or dual ET-receptor antagonist bosentan (100mg/kg) for 4-weeks starting at 18-weeks after established cerebrovascular dysfunction (n=5-6/group). Control group included vehicle-treated aged-matched Wistar rats. Blood glucose and pressure were monitored weekly. At termination, basilar arteries were collected and cumulative dose-response curves to ET-1 (0.1-500 nM), 5-HT (1-1000 nM) and acetylcholine (Ach, 0.1 nM-5 μM) were studied by wire myograph. Middle cerebral artery (MCA) myogenic reactivity and tone were measured using pressurized arteriograph. KEY FINDINGS: There was no difference in ET-1 and 5-HT-mediated constrictions. Endothelium-dependent relaxation was impaired in diabetes. Bosentan improved sensitivity to Ach as well as the maximum relaxation. Myogenic-tone is decreased over the course of the disease. Both treatments improved the ability of MCAs to develop tone at 80 mm Hg and only bosentan improved the tone at higher pressures. SIGNIFICANCE: These results suggest that contractile response is not affected by glycemic control or ET-receptor antagonism. Meanwhile, dual ET-receptor blockade is effective in partially improving endothelium-dependent relaxation and myogenic response in a blood pressure-independent manner even after established cerebrovascular dysfunction and offers therapeutic potential. Published by Elsevier Inc.
Authors: Aaron S Dumont; Randall J Dumont; John H McNeill; Neal F Kassell; Garnette R Sutherland; Subodh Verma Journal: Neurosurgery Date: 2003-03 Impact factor: 4.654
Authors: Kamakshi Sachidanandam; Jim R Hutchinson; Mostafa M Elgebaly; Erin M Mezzetti; Anne M Dorrance; Kouros Motamed; Adviye Ergul Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-01-28 Impact factor: 3.619
Authors: A Sánchez; P Martínez; M Muñoz; S Benedito; A García-Sacristán; M Hernández; D Prieto Journal: Br J Pharmacol Date: 2014-12 Impact factor: 8.739
Authors: Shaoxun Wang; Wenshan Lv; Huawei Zhang; Yedan Liu; Longyang Li; Joshua R Jefferson; Ya Guo; Man Li; Wenjun Gao; Xing Fang; Ian A Paul; Grazyna Rajkowska; James P Shaffery; Thomas H Mosley; Xinlin Hu; Ruen Liu; Yangang Wang; Hongwei Yu; Richard J Roman; Fan Fan Journal: Geroscience Date: 2020-07-21 Impact factor: 7.713